Vertex, J&J and Glaxo collaborating on hepatitis C therapies

Posted on November 1st, by Michael Shapiro-Barr

Vertex Pharmaceuticals Inc. has agreed to test one of its experimental therapies for hepatitis C with other drugs from Johnson & Johnson and GlaxoSmithKline Plc.  Combination therapy has become the most effective approach to combating hepatitis C, due to the fact that the combination of different kinds of drugs will address the various ways the virus infects the body.

Read More

Comments are closed.